Top

Journal of Cancer Research and Clinical Oncology

Published in:

Open Access 01-08-2021 | Glioblastoma | Original Article – Cancer Research

Integrated analysis of programmed cell death ligand 1 expression reveals increased levels in high-grade glioma

Authors: Dorothee Hölzl, Georg Hutarew, Barbara Zellinger, Hans U. Schlicker, Christoph Schwartz, Peter A. Winkler, Karl Sotlar, Theo F. J. Kraus

Published in: Journal of Cancer Research and Clinical Oncology | Issue 8/2021

Abstract

Purpose

Gliomas are the most frequent primary brain tumors of adults. Despite intensive research, there are still no targeted therapies available. Here, we performed an integrated analysis of glioma and programmed cell death ligand 1 (PD-L1) in 90 samples including 58 glioma and 32 control brain tissues.

Methods

To identify PD-L1 expression in glioma, we performed immunohistochemical analysis of PD-L1 tumor proportion score (TPS) using the clinically valid PD-L1 22C3 antibody on 90 samples including controls and WHO grade I–IV gliomas.

Results

We found that PD-L1 is highly expressed in a subfraction of glioma cells. Analysis of PD-L1 levels in different glioma subtypes revealed a strong intertumoral variation of PD-L1 protein. Furthermore, we correlated PD-L1 expression with molecular glioma hallmarks such as MGMT-promoter methylation, IDH1/2 mutations, TERT promoter mutations and LOH1p/19q.

Conclusion

In summary, we found that PD-L1 is highly expressed in a subfraction of glioma, indicating PD-L1 as a potential new marker in glioma assessment opening up novel therapeutic approaches.

Berghoff AS, Kiesel B, Widhalm G, Wilhelm D, Rajky O, Kurscheid S, Kresl P, Wohrer A, Marosi C, Hegi ME, Preusser M (2017) Correlation of immune phenotype with IDH mutation in diffuse glioma. Neuro Oncol 19(11):1460–1468. https://doi.org/10.1093/neuonc/nox054CrossRefPubMedPubMedCentral

Campesato LF, Barroso-Sousa R, Jimenez L, Correa BR, Sabbaga J, Hoff PM, Reis LF, Galante PA, Camargo AA (2015) Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice. Oncotarget 6(33):34221–34227. https://doi.org/10.18632/oncotarget.5950CrossRefPubMedPubMedCentral

Fan Y, Che X, Qu J, Hou K, Wen T, Li Z, Li C, Wang S, Xu L, Liu Y, Qu X (2019) Exosomal PD-L1 retains immunosuppressive activity and is associated with gastric cancer prognosis. Ann Surg Oncol 26(11):3745–3755. https://doi.org/10.1245/s10434-019-07431-7CrossRefPubMed

Fujita Y, Yagishita S, Hagiwara K, Yoshioka Y, Kosaka N, Takeshita F, Fujiwara T, Tsuta K, Nokihara H, Tamura T, Asamura H, Kawaishi M, Kuwano K, Ochiya T (2015) The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer. Mol Ther 23(4):717–727. https://doi.org/10.1038/mt.2015.10CrossRefPubMedPubMedCentral

Gatalica Z, Snyder C, Maney T, Ghazalpour A, Holterman DA, Xiao N, Overberg P, Rose I, Basu GD, Vranic S, Lynch HT, Von Hoff DD, Hamid O (2014) Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomark Prev 23(12):2965–2970. https://doi.org/10.1158/1055-9965.EPI-14-0654CrossRef

Gonzalez Castro LN, Wesseling P (2021) The cIMPACT-NOW updates and their significance to current neuro-oncology practice. Neurooncol Pract 8(1):4–10. https://doi.org/10.1093/nop/npaa055CrossRefPubMed

Hao C, Chen G, Zhao H, Li Y, Chen J, Zhang H, Li S, Zhao Y, Chen F, Li W, Jiang WG (2020) PD-L1 expression in glioblastoma, the clinical and prognostic significance: a systematic literature review and meta-analysis. Front Oncol 10:1015. https://doi.org/10.3389/fonc.2020.01015CrossRefPubMedPubMedCentral

Hau P, Stupp R, Hegi ME (2007) MGMT methylation status: the advent of stratified therapy in glioblastoma? Dis Mark 23(1–2):97–104CrossRef

Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N, Stupp R (2004) Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10(6):1871–1874CrossRefPubMed

Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003. https://doi.org/10.1056/NEJMoa043331CrossRefPubMed

Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP, Gilbert MR (2008) Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26(25):4189–4199. https://doi.org/10.1200/JCO.2007.11.5964CrossRefPubMed

Hegi ME, Sciuscio D, Murat A, Levivier M, Stupp R (2009) Epigenetic deregulation of DNA repair and its potential for therapy. Clin Cancer Res 15(16):5026–5031. https://doi.org/10.1158/1078-0432.CCR-08-1169CrossRefPubMed

Hegi ME, Janzer RC, Lambiv WL, Gorlia T, Kouwenhoven MC, Hartmann C, von Deimling A, Martinet D, Besuchet Schmutz N, Diserens AC, Hamou MF, Bady P, Weller M, van den Bent MJ, Mason WP, Mirimanoff RO, Stupp R, Mokhtari K, Wesseling P, European Organisation for R, Treatment of Cancer Brain T, Radiation Oncology G, National Cancer Institute of Canada Clinical Trials G (2012) Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta Neuropathol 123(6):841–852. https://doi.org/10.1007/s00401-011-0938-4CrossRefPubMed

Heiland DH, Haaker G, Delev D, Mercas B, Masalha W, Heynckes S, Gabelein A, Pfeifer D, Carro MS, Weyerbrock A, Prinz M, Schnell O (2017) Comprehensive analysis of PD-L1 expression in glioblastoma multiforme. Oncotarget 8(26):42214–42225. https://doi.org/10.18632/oncotarget.15031CrossRefPubMedPubMedCentral

Honda Y, Otsuka A, Ono S, Yamamoto Y, Seidel JA, Morita S, Hirata M, Kataoka TR, Takenouchi T, Fujii K, Kanekura T, Okubo Y, Takahashi K, Yanagi T, Hoshina D, Hata H, Abe R, Fujimura T, Funakoshi T, Yoshino K, Masuzawa M, Amoh Y, Tanaka R, Fujisawa Y, Honda T, Kabashima K (2017) Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma. Oncoimmunology 6(1):e1253657. https://doi.org/10.1080/2162402X.2016.1253657CrossRefPubMed

Ilie M, Khambata-Ford S, Copie-Bergman C, Huang L, Juco J, Hofman V, Hofman P (2017) Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms. PLoS ONE 12(8):e0183023. https://doi.org/10.1371/journal.pone.0183023CrossRefPubMedPubMedCentral

Isaacsson Velho P, Antonarakis ES (2018) PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. Expert Rev Clin Pharmacol 11(5):475–486. https://doi.org/10.1080/17512433.2018.1464388CrossRefPubMed

Kaina B, Christmann M, Naumann S, Roos WP (2007) MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair 6(8):1079–1099. https://doi.org/10.1016/j.dnarep.2007.03.008CrossRefPubMed

Kataoka K, Ogawa S (2016) Genetic biomarkers for PD-1/PD-L1 blockade therapy. Oncoscience 3(11–12):311–312. https://doi.org/10.18632/oncoscience.328CrossRefPubMedPubMedCentral

Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, Nagano S, Maeda T, Nagata Y, Kitanaka A, Mizuno S, Tanaka H, Chiba K, Ito S, Watatani Y, Kakiuchi N, Suzuki H, Yoshizato T, Yoshida K, Sanada M, Itonaga H, Imaizumi Y, Totoki Y, Munakata W, Nakamura H, Hama N, Shide K, Kubuki Y, Hidaka T, Kameda T, Masuda K, Minato N, Kashiwase K, Izutsu K, Takaori-Kondo A, Miyazaki Y, Takahashi S, Shibata T, Kawamoto H, Akatsuka Y, Shimoda K, Takeuchi K, Seya T, Miyano S, Ogawa S (2016) Aberrant PD-L1 expression through 3’-UTR disruption in multiple cancers. Nature 534(7607):402–406. https://doi.org/10.1038/nature18294CrossRefPubMed

Kraus TF, Greiner A, Steinmaurer M, Dietinger V, Guibourt V, Kretzschmar HA (2015a) Genetic characterization of ten-eleven-translocation methylcytosine dioxygenase alterations in human glioma. J Cancer 6(9):832–842. https://doi.org/10.7150/jca.12010CrossRefPubMedPubMedCentral

Kraus TF, Kolck G, Greiner A, Schierl K, Guibourt V, Kretzschmar HA (2015b) Loss of 5-hydroxymethylcytosine and intratumoral heterogeneity as an epigenomic hallmark of glioblastoma. Tumour Biol. https://doi.org/10.1007/s13277-015-3606-9CrossRefPubMed

Kraus TFJ, Machegger L, Poppe J, Zellinger B, Dovjak E, Schlicker HU, Schwartz C, Ladisich B, Spendel M, Kral M, Reinhardt A, Winkler PA, Sotlar K (2020) Diffuse midline glioma of the cervical spinal cord with H3 K27M genotype phenotypically mimicking anaplastic ganglioglioma: a case report and review of the literature. Brain Tumor Pathol 37(3):89–94. https://doi.org/10.1007/s10014-020-00365-zCrossRefPubMedPubMedCentral

Li X, Wetherilt CS, Krishnamurti U, Yang J, Ma Y, Styblo TM, Meisel JL, Peng L, Siddiqui MT, Cohen C, Aneja R (2016) Stromal PD-L1 expression is associated with better disease-free survival in triple-negative breast cancer. Am J Clin Pathol 146(4):496–502. https://doi.org/10.1093/ajcp/aqw134CrossRefPubMed

Li C, Huang C, Mok TS, Zhuang W, Xu H, Miao Q, Fan X, Zhu W, Huang Y, Lin X, Jiang K, Hu D, Chen X, Huang P, Lin G (2017) Comparison of 22C3 PD-L1 expression between surgically resected specimens and paired tissue microarrays in non-small cell lung cancer. J Thorac Oncol 12(10):1536–1543. https://doi.org/10.1016/j.jtho.2017.07.015CrossRefPubMed

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97–109. https://doi.org/10.1007/s00401-007-0243-4CrossRefPubMedPubMedCentral

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016a) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820. https://doi.org/10.1007/s00401-016-1545-1CrossRefPubMed

Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C, Paulus W, Perry A, Reifenberger G, Figarella-Branger D, Wesseling P, Batchelor TT, Gregory Cairncross J, Pfister SM, Rutkowski S, Weller M, Wick W, von Deimling A (2016b) cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification. Brain Pathol. https://doi.org/10.1111/bpa.12457CrossRefPubMedPubMedCentral

Louis DN, Wesseling P, Aldape K, Brat DJ, Capper D, Cree IA, Eberhart C, Figarella-Branger D, Fouladi M, Fuller GN, Giannini C, Haberler C, Hawkins C, Komori T, Kros JM, Ng HK, Orr BA, Park SH, Paulus W, Perry A, Pietsch T, Reifenberger G, Rosenblum M, Rous B, Sahm F, Sarkar C, Solomon DA, Tabori U, van den Bent MJ, von Deimling A, Weller M, White VA, Ellison DW (2020) cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol 30(4):844–856. https://doi.org/10.1111/bpa.12832CrossRefPubMedPubMedCentral

Nduom EK, Wei J, Yaghi NK, Huang N, Kong LY, Gabrusiewicz K, Ling X, Zhou S, Ivan C, Chen JQ, Burks JK, Fuller GN, Calin GA, Conrad CA, Creasy C, Ritthipichai K, Radvanyi L, Heimberger AB (2016) PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol 18(2):195–205. https://doi.org/10.1093/neuonc/nov172CrossRefPubMed

Neuman T, London M, Kania-Almog J, Litvin A, Zohar Y, Fridel L, Sandbank J, Barshak I, Vainer GW (2016) a harmonization study for the use of 22C3 PD-L1 immunohistochemical staining on Ventana’s platform. J Thorac Oncol 11(11):1863–1868. https://doi.org/10.1016/j.jtho.2016.08.146CrossRefPubMed

Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X (2015) Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 21(1):24–33. https://doi.org/10.1016/j.molmed.2014.10.009CrossRefPubMed

Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O’Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR, Investigators K (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823–1833. https://doi.org/10.1056/NEJMoa1606774CrossRefPubMed

Roge R, Vyberg M, Nielsen S (2017) Accurate PD-L1 protocols for non-small cell lung cancer can be developed for automated staining platforms with Clone 22C3. Appl Immunohistochem Mol Morphol 25(6):381–385. https://doi.org/10.1097/PAI.0000000000000534CrossRefPubMed

Said EA, Dupuy FP, Trautmann L, Zhang Y, Shi Y, El-Far M, Hill BJ, Noto A, Ancuta P, Peretz Y, Fonseca SG, Van Grevenynghe J, Boulassel MR, Bruneau J, Shoukry NH, Routy JP, Douek DC, Haddad EK, Sekaly RP (2010) Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nat Med 16(4):452–459. https://doi.org/10.1038/nm.2106CrossRefPubMedPubMedCentral

Sun C, Mezzadra R, Schumacher TN (2018) Regulation and function of the PD-L1 checkpoint. Immunity 48(3):434–452. https://doi.org/10.1016/j.immuni.2018.03.014CrossRefPubMedPubMedCentral

Title: Integrated analysis of programmed cell death ligand 1 expression reveals increased levels in high-grade glioma
Authors: Dorothee Hölzl
Georg Hutarew
Barbara Zellinger
Hans U. Schlicker
Christoph Schwartz
Peter A. Winkler
Karl Sotlar
Theo F. J. Kraus
Publication date: 01-08-2021
Publisher: Springer Berlin Heidelberg
Keywords: Glioblastoma
Astrocytoma
Glioma
Glioma
Astrocytoma
Glioblastoma
Brain Tumor
Targeted Therapy
Astrocytoma
Glioblastoma
Glioma
Published in: Journal of Cancer Research and Clinical Oncology / Issue 8/2021
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-021-03656-w

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2021

Adjuvant radiotherapy and chemotherapy offer a recurrence and survival benefit in patients with resected perihilar cholangiocarcinoma

Treatment stage migration and treatment sequences in patients with hepatocellular carcinoma: drawbacks and opportunities

The ability of post-chemoradiotherapy DWI ADCmean and 18F-FDG SUVmax to predict treatment outcomes in head and neck cancer: impact of human papilloma virus oropharyngeal cancer status

Is the prediction of one or two ipsilateral positive lymph nodes by computerized tomography and ultrasound reliable enough to restrict therapeutic neck dissection in oral squamous cell carcinoma (OSCC) patients?

Expression of ISL1 and its partners in prostate cancer progression and neuroendocrine differentiation

Testicular cancer follow-up costs in Germany from 2000 to 2015

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage